As we know, it is necessary to produce the passage of L-DOPA administered to the blood brain barrier (BBB) to supplement the lack of dopamine suffered by patients with Parkinson's.
On the other hand, the possibility of blocking peripheral decarboxylation by adding an aromatic amino acid decarboxylase (AADC) inhibitor has been studied.